(Q34992535)

English

A phase I factorial design study of dose-dense temozolomide alone and in combination with thalidomide, isotretinoin, and/or celecoxib as postchemoradiation adjuvant therapy for newly diagnosed glioblastoma

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

5 August 2017

A phase I factorial design study of dose-dense temozolomide alone and in combination with thalidomide, isotretinoin, and/or celecoxib as postchemoradiation adjuvant therapy for newly diagnosed glioblastoma (English)

1 reference

Europe PubMed Central

PubMed publication ID

5 August 2017

0 references

0 references

author name string

Mark R Gilbert

1

1 reference

Europe PubMed Central

PubMed publication ID

5 August 2017

Javier Gonzalez

2

1 reference

Europe PubMed Central

PubMed publication ID

5 August 2017

Kathy Hunter

3

1 reference

Europe PubMed Central

PubMed publication ID

5 August 2017

Kenneth Hess

4

1 reference

Europe PubMed Central

PubMed publication ID

5 August 2017

Pierre Giglio

5

1 reference

Europe PubMed Central

PubMed publication ID

5 August 2017

Eric Chang

6

1 reference

Europe PubMed Central

PubMed publication ID

5 August 2017

Vinay Puduvalli

7

1 reference

Europe PubMed Central

PubMed publication ID

5 August 2017

Morris D Groves

8

1 reference

Europe PubMed Central

PubMed publication ID

5 August 2017

Howard Colman

9

1 reference

Europe PubMed Central

PubMed publication ID

5 August 2017

Charles Conrad

10

1 reference

Europe PubMed Central

PubMed publication ID

5 August 2017

Victor Levin

11

1 reference

Europe PubMed Central

PubMed publication ID

5 August 2017

Shaio Woo

12

1 reference

Europe PubMed Central

PubMed publication ID

5 August 2017

Anita Mahajan

13

1 reference

Europe PubMed Central

PubMed publication ID

5 August 2017

John de Groot

14

1 reference

Europe PubMed Central

PubMed publication ID

5 August 2017

W K Alfred Yung

15

1 reference

Europe PubMed Central

PubMed publication ID

5 August 2017

language of work or name

1 reference

based on heuristic

inferred from title

publication date

20 August 2010

1 reference

Europe PubMed Central

PubMed publication ID

5 August 2017

1 reference

Europe PubMed Central

PubMed publication ID

5 August 2017

12

1 reference

Europe PubMed Central

PubMed publication ID

5 August 2017

11

1 reference

Europe PubMed Central

PubMed publication ID

5 August 2017

1167-1172

1 reference

Europe PubMed Central

PubMed publication ID

5 August 2017

copyright license

Creative Commons Attribution-NonCommercial 2.5 Generic

4 October 2016

1 reference

April 2022 Public Data File from Crossref

copyright status

0 references

Thrombosis associated with angiogenesis inhibitors.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3098026

8 July 2018

Rechallenge with temozolomide in patients with recurrent gliomas

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3098026

8 July 2018

TRAIL-mediated apoptosis in malignant glioma cells is augmented by celecoxib through proteasomal degradation of survivin

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3098026

8 July 2018

Population-based studies on incidence, survival rates, and genetic alterations in astrocytic and oligodendroglial gliomas

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3098026

8 July 2018

MGMT gene silencing and benefit from temozolomide in glioblastoma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3098026

8 July 2018

Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3098026

8 July 2018

Differential effects of selective COX-2 inhibitors on cell cycle regulation and proliferation of glioblastoma cell lines

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3098026

8 July 2018

Selective CD4+ lymphopenia in melanoma patients treated with temozolomide: a toxicity with therapeutic implications

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3098026

8 July 2018

Phase II evaluation of temozolomide and 13-cis-retinoic acid for the treatment of recurrent and progressive malignant glioma: a North American Brain Tumor Consortium study

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3098026

8 July 2018

Marked inactivation of O6-alkylguanine-DNA alkyltransferase activity with protracted temozolomide schedules

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3098026

8 July 2018

A phase II study of temozolomide in patients with newly diagnosed supratentorial malignant glioma before radiation therapy

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3098026

8 July 2018

Promising survival for patients with newly diagnosed glioblastoma multiforme treated with concomitant radiation plus temozolomide followed by adjuvant temozolomide

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3098026

8 July 2018

A phase II study of temozolomide vs. procarbazine in patients with glioblastoma multiforme at first relapse

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3098026

8 July 2018

The effect of celecoxib, a cyclooxygenase-2 inhibitor, in familial adenomatous polyposis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3098026

8 July 2018

Phase II trial of the antiangiogenic agent thalidomide in patients with recurrent high-grade gliomas

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3098026

8 July 2018

A multicenter cohort study of dose-dense temozolomide (21 of 28 days) for the treatment of recurrent anaplastic astrocytoma or oligoastrocytoma.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3098026

26 October 2018

A North American brain tumor consortium (NABTC 99-04) phase II trial of temozolomide plus thalidomide for recurrent glioblastoma multiforme

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3098026

26 October 2018

Combination celecoxib and temozolomide in C6 rat glioma orthotopic model.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3098026

26 October 2018

One week on/one week off: a novel active regimen of temozolomide for recurrent glioblastoma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3098026

26 October 2018

Phase II trial of temozolomide plus the matrix metalloproteinase inhibitor, marimastat, in recurrent and progressive glioblastoma multiforme

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3098026

26 October 2018

Treatment of recurrent malignant gliomas with high-dose 13-cis-retinoic acid.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3098026

26 October 2018

Response criteria for phase II studies of supratentorial malignant glioma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3098026

26 October 2018

Identifiers

10.1093/NEUONC/NOQ100

1 reference

Europe PubMed Central

PubMed publication ID

5 August 2017

Internet Archive ID

pubmed-PMC3098026

0 references

PMC publication ID

1 reference

Europe PubMed Central

PubMed publication ID

5 August 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

5 August 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q34992535&oldid=1870090713"